Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GMNN | O75496 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28289386 | 0.88 | CYP1A2 (0.77) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL22116262 | 0.88 | CYP1A2 (0.77) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL22116165 | 0.88 | CYP1A2 (0.77) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL29440234 | 0.88 | CYP1A2 (0.82) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| Butyryl-Carnitine SCHEMBL3902301 | 0.88 | CYP1A2 (0.77) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL22116167 | 0.88 | CYP1A2 (0.82) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5421346 | 0.87 | MEN1 (0.69) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5421345 | 0.87 | MEN1 (0.69) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL22057079 | 0.87 | CYP1A2 (0.66) | CYP1A2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL29652051 | 0.87 | MAPK1 (0.83) | CYP1A2MEN1KMT2AMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034833-B2 | Phosphorus binder for treatment of renal disease | BIOLINK LIFE SCIENCES, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090239914-A1 | Phosphorus binder for treatment of renal disease | BIOLINK LIFE SCIENCES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7572832-B2 | Non-hygroscopic L-carnitine salts | BIOLINK LIFE SCIENCES, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| WO-2008116215-A2 | PHOSPHORUS BINDER FOR TREATMENT OF RENAL DISEASE | BIOLINK LIFE SCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234371-A1 | Non-hygroscopic L-carnitine salts | BIOLINK LIFE SCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008115915-A2 | NON-HYGROSCOPIC L-CARNITINE SALTS | BIOLINK LIFE SCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239914-A1 | Phosphorus binder for treatment of renal disease | ALPI, PHPT1, FABP2 | CYP1A2 3238/4885MEN1 2872/4885KMT2A 3908/4885 |
| US-20080234371-A1 | Non-hygroscopic L-carnitine salts | CRAT, SLC25A20, CPT1B | CYP1A2 2226/4885MEN1 2186/4885KMT2A 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.